Mr. Wolfgang Probst reports

BIONXT SOLUTIONS ANNOUNCES OPTION GRANTS

Bionxt Solutions Inc. has granted an aggregate of 750,000 stock options, pursuant to the company's stock option plan, to certain insiders, consultants and an employee of the company, each option entitling the holder thereof to acquire one common share of the company at an exercise price of 33 cents for a period of three years. All such options vested immediately.

Additionally, the company granted an aggregate of 2.65 million options pursuant to the option plan to certain insiders and a consultant of the company, each option entitling the holder thereof to acquire one common share of the company at an exercise price of 33 cents for a period of five years. All such options vested immediately.

The option plan was last approved by the shareholders of the company on Nov. 7, 2025.

The options and any underlying common shares in the capital of the company will be subject to a four-month hold period pursuant to the policies of the Canadian Securities Exchange.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumours while reducing side effects.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange and OTC Markets, and trades in Germany.